Literature DB >> 9495837

Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.

C Ghelardini1, N Galeotti, F Gualtieri, V Marchese, C Bellucci, A Bartolini.   

Abstract

The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests. (+/-)-PG-9 antinociception peaked 15 min after injection and then slowly diminished. The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test. Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels. In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9495837

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Effects of the selective M1 muscarinic receptor antagonist dicyclomine on emotional memory.

Authors:  R V Fornari; K M Moreira; M G Oliveira
Journal:  Learn Mem       Date:  2000 Sep-Oct       Impact factor: 2.460

2.  The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide.

Authors:  Surabi Veeraragavan; Nghiem Bui; Jennie R Perkins; Lisa A Yuva-Paylor; Richard Paylor
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

3.  Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome.

Authors:  Surabi Veeraragavan; Nghiem Bui; Jennie R Perkins; Lisa A Yuva-Paylor; Randall L Carpenter; Richard Paylor
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

4.  DMSO Delays Alzheimer Disease Causing Aβ-induced Paralysis in C. elegans Through Modulation of Glutamate/Acetylcholine Neurotransmission.

Authors:  Girish Sadananda; Janaki Devi Velmurugan; Jamuna R Subramaniam
Journal:  Ann Neurosci       Date:  2021-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.